A case of imatinib-resistant GIST treated by sunitinib

Yasuo Sakamoto, Hisafumi Akimoto, Miyako Kojo, Hiroyuki Kawano, Yoshiki Chinen, Kazutoyo Morita, Masahiko Sugiyama, Hiroshi Saeki, Kazuhito Minami, Yuji Soejima, Yoshihisa Sakaguchi, Yasushi Toh, Takeshi Okamura

Research output: Contribution to journalArticle

Abstract

We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300 mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400 mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.

Original languageEnglish
Pages (from-to)827-830
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number5
Publication statusPublished - May 15 2011

Fingerprint

Neoplasms
Neoplasm Metastasis
Pancreatectomy
Liver
Splenectomy
Gastrectomy
Imatinib Mesylate
sunitinib
Fever
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sakamoto, Y., Akimoto, H., Kojo, M., Kawano, H., Chinen, Y., Morita, K., ... Okamura, T. (2011). A case of imatinib-resistant GIST treated by sunitinib. Japanese Journal of Cancer and Chemotherapy, 38(5), 827-830.

A case of imatinib-resistant GIST treated by sunitinib. / Sakamoto, Yasuo; Akimoto, Hisafumi; Kojo, Miyako; Kawano, Hiroyuki; Chinen, Yoshiki; Morita, Kazutoyo; Sugiyama, Masahiko; Saeki, Hiroshi; Minami, Kazuhito; Soejima, Yuji; Sakaguchi, Yoshihisa; Toh, Yasushi; Okamura, Takeshi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 5, 15.05.2011, p. 827-830.

Research output: Contribution to journalArticle

Sakamoto, Y, Akimoto, H, Kojo, M, Kawano, H, Chinen, Y, Morita, K, Sugiyama, M, Saeki, H, Minami, K, Soejima, Y, Sakaguchi, Y, Toh, Y & Okamura, T 2011, 'A case of imatinib-resistant GIST treated by sunitinib', Japanese Journal of Cancer and Chemotherapy, vol. 38, no. 5, pp. 827-830.
Sakamoto Y, Akimoto H, Kojo M, Kawano H, Chinen Y, Morita K et al. A case of imatinib-resistant GIST treated by sunitinib. Japanese Journal of Cancer and Chemotherapy. 2011 May 15;38(5):827-830.
Sakamoto, Yasuo ; Akimoto, Hisafumi ; Kojo, Miyako ; Kawano, Hiroyuki ; Chinen, Yoshiki ; Morita, Kazutoyo ; Sugiyama, Masahiko ; Saeki, Hiroshi ; Minami, Kazuhito ; Soejima, Yuji ; Sakaguchi, Yoshihisa ; Toh, Yasushi ; Okamura, Takeshi. / A case of imatinib-resistant GIST treated by sunitinib. In: Japanese Journal of Cancer and Chemotherapy. 2011 ; Vol. 38, No. 5. pp. 827-830.
@article{8fdcf9f00aaa4157914ea9c244980ee2,
title = "A case of imatinib-resistant GIST treated by sunitinib",
abstract = "We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300 mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400 mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.",
author = "Yasuo Sakamoto and Hisafumi Akimoto and Miyako Kojo and Hiroyuki Kawano and Yoshiki Chinen and Kazutoyo Morita and Masahiko Sugiyama and Hiroshi Saeki and Kazuhito Minami and Yuji Soejima and Yoshihisa Sakaguchi and Yasushi Toh and Takeshi Okamura",
year = "2011",
month = "5",
day = "15",
language = "English",
volume = "38",
pages = "827--830",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - A case of imatinib-resistant GIST treated by sunitinib

AU - Sakamoto, Yasuo

AU - Akimoto, Hisafumi

AU - Kojo, Miyako

AU - Kawano, Hiroyuki

AU - Chinen, Yoshiki

AU - Morita, Kazutoyo

AU - Sugiyama, Masahiko

AU - Saeki, Hiroshi

AU - Minami, Kazuhito

AU - Soejima, Yuji

AU - Sakaguchi, Yoshihisa

AU - Toh, Yasushi

AU - Okamura, Takeshi

PY - 2011/5/15

Y1 - 2011/5/15

N2 - We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300 mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400 mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.

AB - We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300 mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400 mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.

UR - http://www.scopus.com/inward/record.url?scp=79960977010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960977010&partnerID=8YFLogxK

M3 - Article

C2 - 21566447

AN - SCOPUS:79960977010

VL - 38

SP - 827

EP - 830

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -